Morgan Stanley’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.45M | Buy |
520,495
+119,304
| +30% | +$606K | ﹤0.01% | 4625 |
|
|
2025
Q4 | $1.71M | Buy |
401,191
+81,903
| +26% | +$311K | ﹤0.01% | 4911 |
|
|
2025
Q3 | $1.02M | Sell |
319,288
-19,918
| -6% | -$44.9K | ﹤0.01% | 5167 |
|
|
2025
Q2 | $770K | Buy |
339,206
+278,622
| +460% | +$449K | ﹤0.01% | 5239 |
|
|
2025
Q1 | $38.5K | Buy |
60,584
+47,383
| +359% | +$36.7K | ﹤0.01% | 6360 |
|
|
2024
Q4 | $13.6K | Sell |
13,201
-37,167
| -74% | -$40K | ﹤0.01% | 6695 |
|
|
2024
Q3 | $59.4K | Sell |
50,368
-138,118
| -73% | -$175K | ﹤0.01% | 6165 |
|
|
2024
Q2 | $230K | Sell |
188,486
-667,498
| -78% | -$1.33M | ﹤0.01% | 5601 |
|
|
2024
Q1 | $1.87M | Buy |
855,984
+698,142
| +442% | +$1.29M | ﹤0.01% | 4633 |
|
|
2023
Q4 | $245K | Buy |
157,842
+94,182
| +148% | +$124K | ﹤0.01% | 5866 |
|
|
2023
Q3 | $82.1K | Sell |
63,660
-20,616
| -24% | -$32.5K | ﹤0.01% | 5975 |
|
|
2023
Q2 | $145K | Sell |
84,276
-67,099
| -44% | -$111K | ﹤0.01% | 5783 |
|
|
2023
Q1 | $229K | Buy |
151,375
+133,426
| +743% | +$302K | ﹤0.01% | 5655 |
|
|
2022
Q4 | $28.7K | Buy |
17,949
+2,896
| +19% | +$4.29K | ﹤0.01% | 6537 |
|
|
2022
Q3 | $22K | Sell |
15,053
-146,368
| -91% | -$225K | ﹤0.01% | 6745 |
|
|
2022
Q2 | $295K | Buy |
161,421
+83,767
| +108% | +$160K | ﹤0.01% | 5696 |
|
|
2022
Q1 | $206K | Sell |
77,654
-9,589
| -11% | -$36.8K | ﹤0.01% | 5911 |
|
|
2021
Q4 | $376K | Sell |
87,243
-30,989
| -26% | -$182K | ﹤0.01% | 5713 |
|
|
2021
Q3 | $601K | Sell |
118,232
-517,805
| -81% | -$2.77M | ﹤0.01% | 5373 |
|
|
2021
Q2 | $4.03M | Buy |
636,037
+625,307
| +5,828% | +$4.87M | ﹤0.01% | 4006 |
|
|
2021
Q1 | $83K | Sell |
10,730
-290,909
| -96% | -$2.3M | ﹤0.01% | 6107 |
|
|
2020
Q4 | $1.98M | Buy |
301,639
+293,828
| +3,762% | +$2.1M | ﹤0.01% | 4169 |
|
|
2020
Q3 | $52K | Sell |
7,811
-18,118
| -70% | -$134K | ﹤0.01% | 5710 |
|
|
2020
Q2 | $216K | Sell |
25,929
-956
| -4% | -$8.88K | ﹤0.01% | 5042 |
|
|
2020
Q1 | $206K | Sell |
26,885
-40,222
| -60% | -$280K | ﹤0.01% | 4850 |
|
|
2019
Q4 | $557K | Buy |
67,107
+41,846
| +166% | +$282K | ﹤0.01% | 4868 |
|
|
2019
Q3 | $187K | Sell |
25,261
-305,833
| -92% | -$3.02M | ﹤0.01% | 5163 |
|
|
2019
Q2 | $3.71M | Buy |
331,094
+216,330
| +188% | +$2.27M | ﹤0.01% | 3229 |
|
|
2019
Q1 | $1.23M | Buy |
114,764
+30,385
| +36% | +$449K | ﹤0.01% | 3968 |
|
|
2018
Q4 | $1.27M | Sell |
84,379
-11,703
| -12% | -$174K | ﹤0.01% | 4102 |
|
|
2018
Q3 | $1.78M | Sell |
96,082
-14,762
| -13% | -$336K | ﹤0.01% | 4093 |
|
|
2018
Q2 | $2.53M | Sell |
110,844
-23,563
| -18% | -$602K | ﹤0.01% | 3855 |
|
|
2018
Q1 | $3.82M | Buy |
134,407
+34,876
| +35% | +$995K | ﹤0.01% | 3332 |
|
|
2017
Q4 | $2.1M | Sell |
99,531
-96,338
| -49% | -$2M | ﹤0.01% | 3994 |
|
|
2017
Q3 | $3.56M | Buy |
195,869
+122,519
| +167% | +$1.91M | ﹤0.01% | 3320 |
|
|
2017
Q2 | $1.14M | Buy |
73,350
+20,266
| +38% | +$305K | ﹤0.01% | 4274 |
|
|
2017
Q1 | $916K | Sell |
53,084
-10,692
| -17% | -$141K | ﹤0.01% | 4447 |
|
|
2016
Q4 | $701K | Buy |
63,776
+59,041
| +1,247% | +$715K | ﹤0.01% | 4709 |
|
|
2016
Q3 | $75K | Buy |
4,735
+3,574
| +308% | +$43.2K | ﹤0.01% | 5421 |
|
|
2016
Q2 | $12K | Buy |
1,161
+161
| +16% | +$1.84K | ﹤0.01% | 6007 |
|
|
2016
Q1 | $13K | Sell |
1,000
-4,902
| -83% | -$68.1K | ﹤0.01% | 6047 |
|
|
2015
Q4 | $123K | Buy |
+5,902
| New | +$93.4K | ﹤0.01% | 5302 |
|
Other funds holding CTMX
KCM
PA
VA
VCM
